11/10/2009

Researchers said they were surprised to find that once-daily doses of delayed-release mesalamine were as effective at keeping ulcerative colitis in remission as a twice-a-day regimen. The study, presented at the ACG Annual Scientific Meeting, also showed daily dosing improved patient compliance.

Related Summaries